Summit Therapeutics Inc SMMT

Healthcare Biotechnology

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.

NDAQ:SMMT - Post by User

Summit Therapeutics Inc

<< Previous

Bullboard Posts

Post by whytestockson Dec 20, 2024 10:17pm

45 Views

Post# 36373299

Where Will Summit Therapeutics Be in 5 Years?

News; $SMMT Where Will Summit Therapeutics Be in 5 Years?2024-12-20 06:30:00 ET Summit Therapeutics (NASDAQ: SMMT) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. The company's shares are up by 340% since January 2023. The market has high hopes for the biot...SMMT - Where Will Summit Therapeutics Be in 5 Years?

<< Previous

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features